Bruce Booth

Bruce Booth (chief executive) discloses dealings in 4 companies, chiefly Kymera Therapeutics, Inc., Sionna Therapeutics, Inc. and Vigil Neuroscience, Inc. We count 177 filings; the first trade dates from 25 January 2016 and the latest from 29 June 2026.

On the market, this insider has only sold: 167 sales, €55.6M in total. The totals exclude 123 filings filed without an amount. The rest of the record consists of 2 share grants and 5 option exercises. In 2026 alone, the filings show no purchases and 131 sales.

Most recently, on 30 June 2026, the filings show an open-market sale in Kymera Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.